Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
BYL719 - Alpha-specific PI3K inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
NCT04208178 EPIK-B2 (CBYL719G12301)
HER-2 positive breast cancer
Phase 3
548
Progression-free survival (PFS)
Alpelisib + trastuzumab + pertuzumab
Trastuzumab + pertuzumab
Patients with HER2-positive advanced breast cancer with a PIK3CA mutation
Read-out Milesstone(s)
2025
Publication
TBD
NCT04251533 EPIK-B3 (CBYL719H12301)
Triple negative breast cancer
Phase 3
566
Progression-free Survival (PFS) for patients with PIK3CA mutant status
Alpelisib 300 mg + nab-paclitaxel 100 mg/m²
Placebo nab-paclitaxel 100 mg/m²
Patients with advanced triple negative breast cancer with either Phosphoinositide-3-
kinase Catalytic Subunit Alpha (PIK3CA) mutation or Phosphatase and Tensin
Homolog Protein (PTEN) loss without PIK3CA mutation
2023
TBD
99 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation